Best Practice & Research Clinical Anaesthesiology
Volume 22, Issue 3 , Pages 503-517 , September 2008

Transfusion-transmissible infections and transfusion-related immunomodulation

References 

  1. Cane R. Hemoglobin: how much is enough?. Critical Care Medicine. 1990;18:1046–1047
  2. Madjdpour C, Spahn DR, Weiskopf RB. Anemia and perioperative red blood cell transfusion: a matter of tolerance. Critical Care Medicine. 2006;34(5 Suppl):102–108
  3. Consensus conference. Platelet transfusion therapy. JAMA. 1987;257(13):1777–1780
  4. Consensus conference. Fresh-frozen plasma. Indications and risks. JAMA. 1985;253(4):551–553
  5. Madjdpour C, Spahn DR. Allogeneic red blood cell transfusions: efficacy, risks, alternatives and indications. British Journal of Anaesthesia. 2005;95(1):33–42
  6. Hébert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. The New England Journal of Medicine. 1999;340(6):409–417
  7. Gould S, Cimino MJ, Gerber DR. Packed red blood cell transfusion in the intensive care unit: limitations and consequences. American Journal of Critical Care. 2007;16(1):39–49
  8. Group SHoTS . Serious hazards of transfusion. Available from: <http://www.shotuk.org/SHOT%20reports%20&%20Summaries%202006.htm>
  9. Davies A, Staves J, Kay J, et al. End-to-end electronic control of the hospital transfusion process to increase the safety of blood transfusion: strengths and weaknesses. Transfusion. 2006;46(3):352–364
  10. Dzik WH. New technology for transfusion safety. British Journal of Haematology. 2007;136(2):181–190
  11. Busch M, Kleinman S, Nemo G. Current and emerging infectious risks of blood transfusions. JAMA. 2003;289(8):959–962
  12. Cervia J, Wenz B, Ortolano G. Leukocyte reduction's role in the attenuation of infection risks among transfusion recipients. Clinical Infectious Diseases. 2007;45(8):1008–1013
  13. Pealer L, Marfin A, Petersen L, et al. Transmission of West Nile virus through blood transfusion in the United States in 2002. The New England Journal of Medicine. 2003;349(13):1236–1245
  14. Wang J, Lee C, Kao J, et al. Incidence and clinical presentation of posttransfusion TT virus infection in prospectively followed transfusion recipients: emphasis on its relevance to hepatitis. Transfusion. 2000;40(5):596–601
  15. Umemura T, Yeo A, Sottini A, et al. SEN virus infection and its relationship to transfusion-associated hepatitis. Hepatology. 2001;33(5):1303–1311
  16. Kühn J. Transfusion-Associated Infections with Cytomegalovirus and Other Human Herpesviruses. Infusionstherapie und Transfusionsmedizin. 2000;27(3):138–143
  17. Ronghe M, Foot AB, Cornish J, et al. The impact of transfusion of leucodepleted platelet concentrates on cytomegalovirus disease after allogeneic stem cell transplantation. British Journal of Haematology. 2002;118(4):1124–1127
  18. Bowden R, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood. 1995;86(9):3598–3603
  19. Alfieri C, Tanner J, Carpentier L, et al. Epstein-Barr virus transmission from a blood donor to an organ transplant recipient with recovery of the same virus strain from the recipient's blood and oropharynx. Blood. 1996;87(2):812–817
  20. Wagner H, Klüter H, Kruse A, et al. Relevance of transmission of Epstein-Barr virus through blood transfusion. Beiträge zur Infusionstherapie und Transfusionsmedizin. 1994;32:138–141
  21. MacLennan S, Williamson LM. Risks of fresh frozen plasma and platelets. The Journal of Trauma. 2006;60(6 Suppl):S46–S50
  22. Chamberland M, Alter H, Busch M, et al. Emerging infectious disease issues in blood safety. Emerging Infectious Diseases. 2001;7(3 Suppl):552–553
  23. O'Brien S, Yi Q, Fan W, et al. Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services. Transfusion. 2007;47(2):316–325
  24. Parsyan A, Candotti D. Human erythrovirus B19 and blood transfusion - an update. Transfusion Medicine (Oxford, London). 2007;17(4):263–278
  25. Hillyer C, Josephson C, Blajchman M, et al. Bacterial contamination of blood components: risks, strategies, and regulation: joint ASH and AABB educational session in transfusion medicine. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2003;575–589
  26. Blajchman M, Beckers E, Dickmeiss E, et al. Bacterial detection of platelets: current problems and possible resolutions. Transfusion Medicine Reviews. 2005;19(4):259–272
  27. Kuehnert M, Roth V, Haley N, et al. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion. 2001;41(12):1493–1499
  28. Rao PL, Strausbaugh LJ, Liedtke LA, et al. Bacterial infections associated with blood transfusion: experience and perspective of infectious diseases consultants. Transfusion. 2007;47(7):1206–1211
  29. Fang C, Chambers LA, Kennedy J, et al. Detection of bacterial contamination in apheresis platelet products: American Red Cross experience, 2004. Transfusion. 2005;45(12):1845–1852
  30. Kitchen A, Chiodini P. Malaria and blood transfusion. Vox Sanguinis. 2006;90(2):77–84
  31. Nelson J, Kauffmann D, Ciavarella D, et al. Acquired toxoplasmic retinochoroiditis after platelet transfusions. Annals of Ophthalmology. 1989;21(7):253–254
  32. Cardo L, Salata J, Harman R, et al. Leukodepletion filters reduce Leishmania in blood products when used at collection or at the bedside. Transfusion. 2006;46(6):896–902
  33. Cardo L, Asher L. Transfusion medicine illustrated. Electron micrographic study of the removal of Trypanosoma cruzi from blood products by leukodepletion filters. Transfusion. 2006;46(7):1067–1068
  34. Llewelyn C, Hewitt P, Knight R, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet. 2004;363(9407):417–421
  35. Peden A, Head M, Ritchie D, et al. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet. 2004;364(9433):527–529
  36. Wroe S, Pal S, Siddique D, et al. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet. 2006;368(9552):2061–2067
  37. team E. Fourth case of transfusion-associated vCJD infection in the United Kingdom. Euro Surveillance. 2007;12(1):E070118.4
  38. Burnouf T, Padilla A. Current strategies to prevent transmission of prions by human plasma derivatives. Transfusion Clinique et Biologique. 2006;13(5):320–328
  39. Opelz G, Sengar D, Mickey M, et al. Effect of blood transfusions on subsequent kidney transplants. Transplantation Proceedings. 1973;5(1):253–259
  40. Gantt C. Red blood cells for cancer patients. Lancet. 1981;2(8242):363
  41. Busch O, Hop W, Hoynck van Papendrecht M, et al. Blood transfusions and prognosis in colorectal cancer. The New England Journal of Medicine. 1993;328(19):1372–1376
  42. Taylor RW, Manganaro L, O'Brien J, et al. Impact of allogenic packed red blood cell transfusion on nosocomial infection rates in the critically ill patient. Critical Care Medicine. 2002;30(10):2249–2254
  43. Roelen D, van Rood J, Brand A, et al. Immunomodulation by blood transfusions. Vox Sanguinis. 2000;78(2 Suppl):273–275
  44. (TRAP) TtRAtPSG . Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. The New England Journal of Medicine. 1997;337(26):1861–1869
  45. Andreu G, Dewailly J. Prevention of HLA alloimmunization by using leukocyte-depleted components. Current Studies In Hematology and Blood Transfusion. 1994;60:29–40
  46. Naji A. Induction of tolerance by intrathymic inoculation of alloantigen. Current Opinion in Immunology. 1996;8(5):704–709
  47. Mowbray J, Gibbings C, Liddell H, et al. Controlled trial of treatment of recurrent spontaneous abortion by immunisation with paternal cells. Lancet. 1985;1(8435):941–943
  48. Rothstein D, Sayegh M. T-cell costimulatory pathways in allograft rejection and tolerance. Immunological Reviews. 2003;196:85–108
  49. Mincheff M, Meryman H. Costimulatory signals necessary for induction of T cell proliferation. Transplantation. 1990;49(4):768–772
  50. Brand A. Immunological aspects of blood transfusions. Blood Reviews. 2000;14(3):130–144
  51. Sho M, Sandner S, Najafian N, et al. New insights into the interactions between T-cell costimulatory blockade and conventional immunosuppressive drugs. Annals of Surgery. 2002;236(5):667–675
  52. Dzik WH. Mononuclear cell microchimerism and the immunomodulatory effect of transfusion. Transfusion. 1994;34(11):1007–1012
  53. Gafter U, Kalechman Y, Sredni B. Blood transfusion enhances production of T-helper-2 cytokines and transforming growth factor beta in humans. Clinical Science (London). 1996;91(4):519–523
  54. Peters W, Fry R, Fleshman J, et al. Multiple blood transfusions reduce the recurrence rate of Crohn's disease. Diseases of the Colon and Rectum. 1989;32(9):749–753
  55. Lee T, Paglieroni T, Utter G, et al. High-level long-term white blood cell microchimerism after transfusion of leukoreduced blood components to patients resuscitated after severe traumatic injury. Transfusion. 2005;45(8):1280–1290
  56. Utter GH, Nathens AB, Lee T-H, et al. Leukoreduction of blood transfusions does not diminish transfusion-associated microchimerism in trauma patients. Transfusion. 2006;46(11):1863–1869
  57. Reed W, Lee T, Norris P, et al. Transfusion-associated microchimerism: a new complication of blood transfusions in severely injured patients. Seminars in Hematology. 2007;44(1):24–33
  58. Brand A. Immunological aspects of blood transfusions. Transplant Immunology. 2002;10(2-3):183–190
  59. Nielsen H, Reimert C, Pedersen A, et al. Time-dependent, spontaneous release of white cell- and platelet-derived bioactive substances from stored human blood. Transfusion. 1996;36(11–12):960–965
  60. Bury T, Corhay J, Radermecker M. Histamine-induced inhibition of neutrophil chemotaxis and T-lymphocyte proliferation in man. Allergy. 1992;47(6):624–629
  61. Peterson C, Skoog V, Venge P. Human eosinophil cationic proteins (ECP and EPX) and their suppressive effects on lymphocyte proliferation. Immunobiology. 1986;171(1–2):1–13
  62. Ghio M, Contini P, Mazzei C, et al. Soluble HLA class I, HLA class II, and Fas ligand in blood components: a possible key to explain the immunomodulatory effects of allogeneic blood transfusions. Blood. 1999;93(5):1770–1777
  63. Ghio M, Ottonello L, Contini P, et al. Transforming growth factor-beta1 in supernatants from stored red blood cells inhibits neutrophil locomotion. Blood. 2003;102(3):1100–1107
  64. Anderson B, Harken A. Multiple organ failure: inflammatory priming and activation sequences promote autologous tissue injury. The Journal of Trauma. 1990;30(12 Suppl):S44–S49
  65. Silliman CC, Boshkov L, Mehdizadehkashi Z, et al. Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. Blood. 2003;101(2):454–462
  66. Popovsky M, Moore S. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion. 1985;25(6):573–577
  67. King K, Shirey R, Thoman S, et al. Universal leukoreduction decreases the incidence of febrile nonhemolytic transfusion reactions to RBCs. Transfusion. 2004;44(1):1–4
  68. Vamvakas E, Blajchman M. Transfusion-related immunomodulation (TRIM): an update. Blood Reviews. 2007;21(6):327–348
  69. Van de Watering L, Hermans J, Houbiers J, et al. Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: a randomized clinical trial. Circulation. 1998;97(6):562–568
  70. Bilgin Y, Van de Watering L, Eijsman L, et al. Double-blind, randomized controlled trial on the effect of leukocyte-depleted erythrocyte transfusions in cardiac valve surgery. Circulation. 2004;109(22):2755–2760
  71. Wallis J, Chapman C, Orr K, et al. Effect of WBC reduction of transfused RBCs on postoperative infection rates in cardiac surgery. Transfusion. 2002;42(9):1127–1134
  72. Blumberg N, Zhao H, Wang H, et al. The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients. Transfusion. 2007;47(4):573–581
  73. Fergusson D, Khanna MP, Tinmouth A, et al. Transfusion of leukoreduced red blood cells may decrease postoperative infections: two meta-analyses of randomized controlled trials. Canadian Journal of Anaesthesia. 2004;51(5):417–424
  74. Baron J, Gourdin M, Bertrand M, et al. The effect of universal leukodepletion of packed red blood cells on postoperative infections in high-risk patients undergoing abdominal aortic surgery. Anesthesia & Analgesia. 2002;94(3):529–537
  75. Hébert PC, Fergusson D, Blajchman M, et al. Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. JAMA. 2003;289(15):1941–1949
  76. Fergusson D, Hébert PC, Lee S, et al. Clinical outcomes following institution of universal leukoreduction of blood transfusions for premature infants. JAMA. 2003;289(15):1950–1956
  77. Llewelyn C, Taylor R, Todd A, et al. The effect of universal leukoreduction on postoperative infections and length of hospital stay in elective orthopedic and cardiac surgery. Transfusion. 2004;44(4):489–500
  78. Phelan H, Sperry J, Friese R. Leukoreduction before red blood cell transfusion has no impact on mortality in trauma patients. The Journal of Surgical Research. 2007;138(1):32–36
  79. Taylor RW, O'Brien J, Trottier SJ, et al. Red blood cell transfusions and nosocomial infections in critically ill patients. Critical Care Medicine. 2006;34(9):2302–2308
  80. Claridge J, Sawyer R, Schulman A, et al. Blood transfusions correlate with infections in trauma patients in a dose-dependent manner. American Surgeon. 2002;68(7):566–572
  81. Banbury M, Brizzio M, Rajeswaran J, et al. Transfusion increases the risk of postoperative infection after cardiovascular surgery. Journal of the American College of Surgeons. 2006;202(1):131–138
  82. Sreeram G, Welsby I, Sharma A, et al. Infectious complications after cardiac surgery: lack of association with fresh frozen plasma or platelet transfusions. Journal of Cardiothoracic and Vascular Anesthesia. 2005;19(4):430–434
  83. Shorr AF, Jackson WL, Kelly KM, et al. Transfusion practice and blood stream infections in critically ill patients. Chest. 2005;127(5):1722–1728
  84. Hill G, Frawley W, Griffith K, et al. Allogeneic blood transfusion increases the risk of postoperative bacterial infection: a meta-analysis. The Journal of Trauma. 2003;54(5):908–914
  85. Stroncek DF, Rebulla P. Platelet transfusions. Lancet. 2007;370(9585):427–438
  86. Stanworth S, Brunskill S, Hyde C, et al. Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. British Journal of Haematology. 2004;126(1):139–152

PII: S1521-6896(08)00047-5

doi: 10.1016/j.bpa.2008.05.003

Best Practice & Research Clinical Anaesthesiology
Volume 22, Issue 3 , Pages 503-517 , September 2008

Article Tools